These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29855861)

  • 1. Estimated Impact of US Preventive Services Task Force Recommendations on Use and Cost of Statins for Cardiovascular Disease Prevention.
    Ngo-Metzger Q; Zuvekas SH; Bierman AS
    J Gen Intern Med; 2018 Aug; 33(8):1317-1323. PubMed ID: 29855861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations.
    Anderson TS; Wilson LM; Sussman JB
    JAMA Intern Med; 2024 Aug; 184(8):963-970. PubMed ID: 38856978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
    Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
    BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.
    Pagidipati NJ; Navar AM; Mulder H; Sniderman AD; Peterson ED; Pencina MJ
    JAMA; 2017 Apr; 317(15):1563-1567. PubMed ID: 28418481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
    Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
    JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
    Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
    Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.
    Yao X; Shah ND; Gersh BJ; Lopez-Jimenez F; Noseworthy PA
    JAMA Netw Open; 2020 Nov; 3(11):e2025505. PubMed ID: 33216139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal.
    Ngo-Metzger Q; Zuvekas S; Shafer P; Tracer H; Borsky AE; Bierman AS
    J Am Board Fam Med; 2019; 32(6):807-817. PubMed ID: 31704749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
    Jacobs JA; Addo DK; Zheutlin AR; Derington CG; Essien UR; Navar AM; Hernandez I; Lloyd-Jones DM; King JB; Rao S; Herrick JS; Bress AP; Pandey A
    JAMA Cardiol; 2023 May; 8(5):443-452. PubMed ID: 36947031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.
    Mufarreh A; Shah AJ; Vaccarino V; Kulshreshtha A
    JAMA Netw Open; 2023 Jan; 6(1):e2251156. PubMed ID: 36656581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of statin guidelines on statin utilization and costs in an employer-based primary care clinic.
    Gurgle HE; Schauerhamer MB; Rodriguez SA; McAdam-Marx C
    Am J Manag Care; 2017 Dec; 23(12):e387-e393. PubMed ID: 29261246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population.
    Mortensen MB; Nordestgaard BG
    Ann Intern Med; 2018 Jan; 168(2):85-92. PubMed ID: 29297004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.
    Mortensen MB; Afzal S; Nordestgaard BG; Falk E
    J Am Coll Cardiol; 2015 Dec; 66(24):2699-2709. PubMed ID: 26700832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines.
    Pavlović J; Greenland P; Franco OH; Kavousi M; Ikram MK; Deckers JW; Ikram MA; Leening MJG
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007183. PubMed ID: 34546786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.
    Egan BM; Li J; White K; Fleming DO; Connell K; Hernandez GT; Jones DW; Ferdinand KC; Sinopoli A
    J Am Heart Assoc; 2016 Aug; 5(8):. PubMed ID: 27543306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.
    Rodriguez F; Maron DJ; Knowles JW; Virani SS; Lin S; Heidenreich PA
    JAMA Cardiol; 2017 Jan; 2(1):47-54. PubMed ID: 27829091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020.
    Chobufo MD; Regner SR; Zeb I; Lacoste JL; Virani SS; Balla S
    Eur J Prev Cardiol; 2022 Oct; 29(14):1830-1838. PubMed ID: 35653373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.